Cell Projects licenses Electroporation Technologies from Queen’s University, Canada
News Oct 15, 2008
Cell Projects has entered into a wide ranging commercial license and joint development agreement with Queen’s University, Kingston, Ontario, Canada, covering several new Electroporation platform technologies for Adherent and InSitu Cell Electroporation.
The technology allows DNA, peptides, siRNA and many other molecules to be gently transported into cultured, adherent cells while the cells are still attached to their growing surface. The data shows dramatic improvements of sensitivity and operation over existing methodologies.
Tom Hole MD at Cell Projects says “the InSitu technology will enable a greater understanding of specific cellular activities that to date have been difficult to analyze yet are known to be important in further understanding the mechanism of cancer, and other biological problems”.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
Targeting a Leaky Protein that Causes ParalysisNews
A rare genetic disorder in which people are overcome suddenly with profound muscle weakness is caused by a hole in a membrane protein that allows sodium ions to leak across cell membranes. Compounds containing a chemical group called guanidinium can block the pore created by the mutation and stop the sodium leak without altering the voltage sensor’s ability to function.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018